Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (FR:ALCLS)
:ALCLS
Top Page
Cellectis SA
(OTC:ALCLS)
Select Model
Select Model
Rating:51Neutral
Price Target:
€3.00
▲(4.17% Upside)
Cellectis SA's overall stock score is primarily impacted by its financial performance, which is weak due to persistent losses and negative cash flow trends. Technical analysis provides a moderate positive outlook, while the earnings call offers some optimism with progress in clinical trials and strategic partnerships. However, valuation remains a concern due to ongoing losses.
Cellectis SA (ALCLS) vs. iShares MSCI France ETF (EWQ)
Market Cap
$200.42M
Dividend YieldN/A
Average Volume (3M)430.24K
Price to Earnings (P/E)―
Beta (1Y)2.53
Revenue Growth327.14%
EPS Growth49.02%
CountryFR
Employees216
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.21
Shares Outstanding72,093,636
10 Day Avg. Volume797,855
30 Day Avg. Volume430,238
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue1.01
Enterprise Value/Gross Profit1.09
Enterprise Value/Ebitda-1.87
Forecast
1Y Price Target
$2.50Price Target Upside-13.23% Downside
Rating ConsensusHold
Number of Analyst Covering0
Cellectis SA Business Overview & Revenue Model
Company DescriptionCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
How the Company Makes MoneyCellectis generates revenue primarily through partnerships and collaborations with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments associated with the achievement of specific development goals, and royalties on sales of products that result from their collaborations. Additionally, Cellectis may receive funding from government grants or research programs aimed at advancing biotechnology innovations. Its strategic collaborations with major players in the pharmaceutical industry, such as Pfizer and Servier, provide significant revenue opportunities through shared development costs and access to broader markets.
Cellectis SA Earnings Call Summary
Earnings Call Date:Aug 04, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 10, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.Q2-2025 Updates
Positive Updates
Initiation of Pivotal Phase II Trial for lasme-cel
Cellectis is preparing to initiate the pivotal Phase II trial for lasme-cel (UCART22) in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.
Ongoing R&D Partnership with AstraZeneca
Research and development activities continue under the collaboration with AstraZeneca, focusing on three cell and gene therapy programs, including CAR-T for hematological malignancies, CAR-T for solid tumors, and in vivo gene therapy for a genetic disorder.
Strong Financial Position
Cellectis' cash, cash equivalents, and fixed-term deposits as of June 30, 2025, amount to $230 million, sufficient to fund operations into H2 2027.
Upcoming Investor R&D Day
Cellectis will host an Investor R&D Day on October 16, 2025, to present Phase I data and late-stage development strategy for lasme-cel.
Negative Updates
Servier Arbitration
Cellectis is engaged in arbitration with Servier regarding the termination of a licensing agreement, seeking compensation for losses due to lack of development of licensed products. The decision is expected by December 15, 2025.
Decrease in Cash and Equivalents
Cellectis reported a decrease of $33.2 million in cash and equivalents from December 31, 2024, to June 30, 2025, primarily due to operational expenses.
Company Guidance
During Cellectis' Second Quarter 2025 Earnings Call, the company provided guidance on several key metrics. They announced the completion of end-of-Phase I discussions with the FDA and EMA for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia, and their preparation to initiate a pivotal Phase II trial in the second half of 2025. Additionally, the NatHaLi-01 study on UCART20x22 is progressing, with Phase I data anticipated by late 2025. Cellectis is advancing three cell and gene therapy programs under their partnership with AstraZeneca. Financially, the company reported cash, cash equivalents, and fixed-term deposits of $230 million as of June 30, 2025, which are expected to fund operations into the second half of 2027. They are also involved in arbitration with Servier, with a decision expected by December 15, 2025. The company will provide further insights and data during their Investor R&D Day on October 16, 2025.Cellectis SA Financial Statement Overview
Summary
Cellectis SA faces significant financial challenges, with strong gross margins overshadowed by persistent net losses and negative cash flow trends. While revenue growth is a positive sign, the company's profitability and cash generation capabilities remain concerning, impacting its overall financial health.Income Statement
Cellectis SA shows a strong gross profit margin of 98.8% TTM, indicating efficient cost management. However, the company struggles with profitability, as evidenced by a negative net profit margin of -127.1% TTM. Revenue growth is positive at 18.2% TTM, but the negative EBIT and EBITDA margins highlight ongoing operational challenges.45
Neutral
Balance Sheet
The debt-to-equity ratio of 0.79 TTM suggests moderate leverage, but the negative return on equity of -46.1% TTM indicates poor profitability relative to shareholder equity. The equity ratio of 27.4% TTM shows a reasonable level of equity financing, but overall financial stability is a concern due to consistent losses.40
Negative
Cash Flow
Cellectis SA's cash flow is under pressure, with a significant decline in free cash flow growth of -245.4% TTM. The operating cash flow to net income ratio is low at 0.18 TTM, indicating challenges in converting income into cash. The free cash flow to net income ratio of 0.86 TTM suggests some ability to generate cash relative to net losses, but overall cash flow health is weak.30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.30M | 41.51M | 755.00K | 19.17M | 73.95M | 73.95M |
| Gross Profit | 51.86M | 41.51M | 18.00K | 17.40M | 37.67M | 37.67M |
| EBITDA | -30.25M | -9.46M | -92.64M | -76.38M | -85.44M | -43.34M |
| Net Income | -59.00M | -36.76M | -101.06M | -98.69M | -86.28M | -72.57M |
Balance Sheet | ||||||
| Total Assets | 353.97M | 383.54M | 334.27M | 261.22M | 382.08M | 469.47M |
| Cash, Cash Equivalents and Short-Term Investments | 196.15M | 260.31M | 203.81M | 97.70M | 186.13M | 268.24M |
| Total Debt | 94.77M | 91.46M | 85.06M | 82.85M | 102.24M | 111.30M |
| Total Liabilities | 256.86M | 252.51M | 249.57M | 135.28M | 145.60M | 160.63M |
| Stockholders Equity | 97.11M | 131.03M | 84.69M | 117.97M | 221.29M | 275.57M |
Cash Flow | ||||||
| Free Cash Flow | -36.60M | 19.15M | -25.82M | -89.89M | -124.31M | -126.52M |
| Operating Cash Flow | -33.35M | 22.99M | -24.75M | -87.44M | -104.56M | -80.26M |
| Investing Cash Flow | -42.82M | -102.81M | -15.51M | -2.76M | 7.28M | -54.34M |
| Financing Cash Flow | -9.65M | 89.11M | 82.86M | 1.15M | 47.52M | 27.32M |
Cellectis SA Technical Analysis
Positive
2.88
Price Trends
2.54
Positive
1.96
Positive
1.70
Positive
Market Momentum
0.09
Positive
55.74
Neutral
46.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCLS, the sentiment is Positive. The current price of 2.88 is above the 20-day moving average (MA) of 2.74, above the 50-day MA of 2.54, and above the 200-day MA of 1.70, indicating a bullish trend. The MACD of 0.09 indicates Positive momentum. The RSI at 55.74 is Neutral, neither overbought nor oversold. The STOCH value of 46.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALCLS.
Cellectis SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | €161.50M | 4.07 | 58.68% | ― | 3037.72% | ― | |
55 Neutral | €149.61M | -4.06 | -223.43% | ― | 111.76% | -22.45% | |
51 Neutral | $200.42M | ― | -48.02% | ― | 327.14% | 49.02% | |
49 Neutral | €110.02M | -3.91 | -36.00% | ― | ― | 10.87% | |
48 Neutral | €777.39M | -22.92 | 103.70% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
FR:ALCLS
Cellectis SA
2.88
1.07
59.02%
FR:IPH
Innate Pharma SA
1.75
-0.21
-10.53%
FR:NANO
Nanobiotix
16.90
12.22
261.42%
FR:TNG
Transgene
1.13
0.03
2.73%
FR:OSE
OSE Immunotherapeutics SA
7.04
-1.68
-19.23%
FR:ALSEN
Sensorion SAS
0.37
-0.38
-50.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.